"Patienten mit gut- und bösartigen Erkrankungen des Blutes (z.B. Leukämien, Lymphome, Gerinnungsstörungen) wie auch Patienten mit Krebserkrankungen (z.B. Lungenkrebs, Sarkome) stehen im Mittelpunkt unserer Klinik. Eine ganzheitliche Betreuung unserer Patientinnen und Patienten, die Diagnostik, Therapie und Nachsorge, aber auch z.B. die psycho-onkologische Betreuung umfasst, ist unser Ziel. Als Teil des UniversitätsKrebszentrums und des Gesundheitscampus Göttingen gehören Grundlagen- und klinische Forschung zu unseren Kernkompetenzen, wie auch die Aus- und Weiterbildung in allen Gesundheitsberufen."

During the past decade, Uni Göttingen, Georg-August-Universität; Klinik für Hämatologie und Medizinische Onkologie conducted 4 clinical trials. In the 10-year time frame, 4 clinical trials started and 2 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 1 clinical trials were completed. i.e. 50% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Uni Göttingen, Georg-August-Universität; Klinik für Hämatologie und Medizinische Onkologie" #1 collaborator was "AbbVie" with 1 trials as a collaborator, "Genentech, Inc." with 1 trials as a collaborator, "German CLL Study Group" with 1 trials as a collaborator, "German Low Grade Lymphoma Study Group" with 1 trials as a collaborator and "Institute of Cancer Research, United Kingdom" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "Uni Göttingen, Georg-August-Universität; Klinik für Hämatologie und Medizinische Onkologie" are "Adult Solid Tumor" (1 trials), "B-cell Lymphoma" (1 trials), "Breast Cancer" (1 trials), "Cholangiocarcinoma" (1 trials) and "Colorectal Cancer" (1 trials). Many other conditions were trialed in "Uni Göttingen, Georg-August-Universität; Klinik für Hämatologie und Medizinische Onkologie" in a lesser frequency.

Most popular intervention types in "Uni Göttingen, Georg-August-Universität; Klinik für Hämatologie und Medizinische Onkologie" are "Drug" (6 trials). Other intervention types were less common.

The name of intervention was led by "Atezolizumab" (2 trials), "Entrectinib" (2 trials), "Obinutuzumab" (2 trials), "Rituximab" (2 trials) and "Alectinib" (1 trials). Other intervention names were less common.

The vast majority of trials in "Uni Göttingen, Georg-August-Universität; Klinik für Hämatologie und Medizinische Onkologie" are 6 trials for "All" genders.

Currently, there are NaN active trials in "Uni Göttingen, Georg-August-Universität; Klinik für Hämatologie und Medizinische Onkologie". undefined are not yet recruiting, 1 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Uni Göttingen, Georg-August-Universität; Klinik für Hämatologie und Medizinische Onkologie, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Uni Göttingen, Georg-August-Universität; Klinik für Hämatologie und Medizinische Onkologie, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 4 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".